Immunovant, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q4 2018 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Immunovant, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q4 2018 to Q2 2025.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2025 was $18.4M, a 36.8% increase year-over-year.
  • Immunovant, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2025 was $54.4M, a 24.2% increase year-over-year.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $49.5M, a 20.6% increase from 2023.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $41M, a 28.3% increase from 2022.
  • Immunovant, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $32M, a 3.55% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 $54.4M $18.4M +$4.95M +36.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $49.5M $11.7M +$2.02M +20.9% Jan 1, 2025 Mar 31, 2025 10-K 2025-05-29
Q4 2024 $47.4M $11.6M +$1.45M +14.2% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-06
Q3 2024 $46M $12.7M +$2.18M +20.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $43.8M $13.4M +$2.79M +26.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $41M $9.66M +$2.16M +28.8% Jan 1, 2024 Mar 31, 2024 10-K 2025-05-29
Q4 2023 $38.9M $10.2M +$1.34M +15.1% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-06
Q3 2023 $37.5M $10.5M +$2.45M +30.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $35.1M $10.7M +$3.1M +41% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $32M $7.5M -$4.2M -35.9% Jan 1, 2023 Mar 31, 2023 10-K 2025-05-29
Q4 2022 $36.2M $8.86M -$1.1M -11% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 $37.3M $8.05M +$382K +4.98% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $36.9M $7.56M +$3.74M +97.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $33.1M $11.7M +$6.28M +116% Jan 1, 2022 Mar 31, 2022 10-K 2023-05-22
Q4 2021 $26.9M $9.95M +$3.96M +66.1% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-03
Q3 2021 $22.9M $7.67M +$4.36M +132% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-04
Q2 2021 $18.5M $3.82M -$98K -2.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $18.6M $5.42M +$3.62M +201% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-08
Q4 2020 $15M $5.99M +$4.66M +350% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-04
Q3 2020 $10.4M $3.31M +$188K +6.03% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $10.2M $3.92M +$3.38M +630% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $6.79M $1.8M Jan 1, 2020 Mar 31, 2020 10-K 2021-06-01
Q4 2019 $1.33M +$1.32M Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $3.12M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $537K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q4 2018 $12K* Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.